Phase 3 Clinical Trial for Benign Prostatic Hyperplasia Treatment

Dongkook Pharmaceutical 'DKF-313'

[Asia Economy Reporter Seo So-jung] Dongkook Pharmaceutical (Vice Chairman Kwon Ki-beom) held a 'Researcher Meeting' for the Phase 3 clinical trial of 'DKF-313,' a newly improved combination drug for benign prostatic hyperplasia (BPH) under development, and has begun full-scale steps toward the Phase 3 clinical trial.

The DKF-313 researcher meeting, held on the 1st at Seoul Dragon City in Yongsan-gu, Seoul, was attended by researchers from about 20 clinical trial institutions, including Seoul Asan Medical Center, Gangnam Severance Hospital, and Seoul St. Mary's Hospital.

DKF-313, a combination tablet of 'Dutasteride,' which reduces prostate volume, and 'Tadalafil,' which has excellent effects on improving lower urinary tract symptoms, requires only one tablet per day, making it a highly anticipated product in the future prostate combination drug treatment market. Dongkook Pharmaceutical began development in 2012, and after completing toxicity tests, DDI (drug-drug interaction tests), and PK (pharmacokinetic tests), it is now entering Phase 3 clinical trials. If successful, it will become the world's first combination of Dutasteride and Tadalafil.

This Phase 3 clinical trial is designed as a multicenter, randomized, double-blind, double-dummy, three-arm parallel study over 48 weeks to evaluate the efficacy and safety of the combination drug DKF-313 in patients with benign prostatic hyperplasia.

Patient enrollment is scheduled to begin in June, targeting a total of 654 patients aged 45 to 80 diagnosed with benign prostatic hyperplasia. The product launch is aimed for the second half of 2023.

This content was produced with the assistance of AI translation services.